<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>55</volume><submitter>Pentikainen M</submitter><pubmed_abstract>&lt;h4>Objectives&lt;/h4>Given that pulmonary arterial hypertension (PAH) and chronic thromboembolic hypertension (CTEPH) are rare yet severe subtypes of pulmonary hypertension significantly impacting patients' lives, this study analyzed the total societal costs of these conditions in Finland.&lt;h4>Methods&lt;/h4>PAH (n = 247) and CTEPH (n = 177) patients diagnosed between 2008 and 2019 were analyzed for primary and specialty outpatient visits, emergency visits, hospitalizations, home and institutional care, sick leaves, disability pensions, and drug costs for 5 years before and after diagnosis.&lt;h4>Results&lt;/h4>In PAH and CTEPH, annual specialty care number of outpatient visits increased from 3.8 and 3.3 (5 years before diagnosis) to 13.8 and 9.5 one-year post-diagnosis, then decreased to 9.2 and 4.0 </pubmed_abstract><journal>International journal of cardiology. Heart &amp; vasculature</journal><pagination>101534</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11539720</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Economic burden of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland.</pubmed_title><pmcid>PMC11539720</pmcid><pubmed_authors>Tuunanen H</pubmed_authors><pubmed_authors>Harju T</pubmed_authors><pubmed_authors>Heliovaara E</pubmed_authors><pubmed_authors>Majamaa-Voltti K</pubmed_authors><pubmed_authors>Turpeinen A</pubmed_authors><pubmed_authors>Kyllonen T</pubmed_authors><pubmed_authors>Lahelma M</pubmed_authors><pubmed_authors>Vepsalainen V</pubmed_authors><pubmed_authors>Jaaskelainen P</pubmed_authors><pubmed_authors>Puhakka A</pubmed_authors><pubmed_authors>Pentikainen M</pubmed_authors><pubmed_authors>Simonen P</pubmed_authors><pubmed_authors>Leskela P</pubmed_authors><pubmed_authors>Bodker N</pubmed_authors><pubmed_authors>Leskela RL</pubmed_authors><pubmed_authors>FINPAH study group</pubmed_authors><pubmed_authors>Korhonen P</pubmed_authors><pubmed_authors>Wennerstrom C</pubmed_authors><pubmed_authors>Heikkila E</pubmed_authors><pubmed_authors>Kahlos K</pubmed_authors><pubmed_authors>Vihinen T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Economic burden of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) in Finland.</name><description>&lt;h4>Objectives&lt;/h4>Given that pulmonary arterial hypertension (PAH) and chronic thromboembolic hypertension (CTEPH) are rare yet severe subtypes of pulmonary hypertension significantly impacting patients' lives, this study analyzed the total societal costs of these conditions in Finland.&lt;h4>Methods&lt;/h4>PAH (n = 247) and CTEPH (n = 177) patients diagnosed between 2008 and 2019 were analyzed for primary and specialty outpatient visits, emergency visits, hospitalizations, home and institutional care, sick leaves, disability pensions, and drug costs for 5 years before and after diagnosis.&lt;h4>Results&lt;/h4>In PAH and CTEPH, annual specialty care number of outpatient visits increased from 3.8 and 3.3 (5 years before diagnosis) to 13.8 and 9.5 one-year post-diagnosis, then decreased to 9.2 and 4.0 </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-21T22:29:32.22Z</modification><creation>2025-04-05T18:50:36.25Z</creation></dates><accession>S-EPMC11539720</accession><cross_references><pubmed>39507296</pubmed><doi>10.1016/j.ijcha.2024.101534</doi></cross_references></HashMap>